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Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease,
and AD patients are commonly sensitized to house dust mite (HDM). Of the
several treatment options available, allergen‐specific immunotherapy (AIT)
has been recognized as an effective treatment modality that is directed toward
the immunoglobulin E (IgE)‐mediated nature of AD, and subcutaneous
administration using HDM is most commonly used for AIT in AD. For patients
sensitized to animal (dog or cat) dander, the treatment may not be easy,
especially when avoiding the allergen is not possible.
Methods: This study enrolled patients with AD who were sensitized to cat
and/or dog dander and underwent AIT (n = 19). Patients’ medical information
was obtained, including past treatment history, treatment duration of AIT, and
the progress of treatment. Also, the specific IgE levels and IgG4 levels were
measured before and after AIT.
Results: A total of 19 patients with AD underwent AIT using cat and/or
dog dander. The patients consisted of 4 males and 15 females with an
average age of 31.74 ± 9.71. Only two patients had AD only, and the other
17 patients had one or more concomitant allergic diseases, such as allergic
rhinitis, allergic asthma, or allergic conjunctivitis. Seven patients were not
sensitized to HDMs and only sensitized to cat and/or dog dander. The
duration of AIT ranged from 2 to 58 months. The symptoms of 17 patients
were well‐controlled, requiring only topical treatment and/or oral
antihistamines. One patient required systemic cyclosporine, but only of low
dose (25 mg/day). The specific IgE levels were decreased (P = .005) and
IgG4 levels showed the tendency of increasing after AIT. No adverse events
were observed in these patients.
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Conclusion: Although a larger number of patients for a longer follow‐up
period are needed to precisely assess the treatment efficacy, AIT using cat
and/or dog dander may be an effective treatment option for AD patients,
especially for severe AD patients with other respiratory allergic comorbidities
who cannot completely avoid the exposure to animal dander.
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Atopic dermatitis (AD) is a chronic inflammatory skin
disorder characterized by relapsing eczematous skin
lesions with marked pruritus. It is a multifactorial
disorder that results from genetic susceptibility with
barrier disruption and immune dysregulation, in ad-
dition to environmental triggers.1 A major portion of
the patients is sensitized to allergens, most commonly
to house dust mite (HDM), in which serum total im-
munoglobulin E (IgE) and specific IgE to certain al-
lergens are found to be increased.2 For these sensitized
patients, among various available treatment options,
allergen‐specific immunotherapy (AIT) is the treat-
ment that is directed towards the IgE‐mediated nature
of the disease.3
AIT has been used in allergic diseases, more pre-
dominantly in allergic rhinitis and allergic asthma, for
the past decades.3 Although the evidence of its efficacy
may not be as concrete in AD, studies suggesting the
effectiveness in AD is steadily increasing.4 In comparison
to AIT in other allergic diseases that use various kinds of
allergens (eg, pollen, HDM, animal danders), the effec-
tiveness of AIT in AD has been established in patients
sensitized to HDM.5 Although HDM is predominant al-
lergen sensitized in AD patients, some patients are con-
comitantly sensitized to other allergens or may be
sensitized to allergens other than HDM in some cases.6
Among the various allergens, animal dander, particularly
cat and dog dander, can be found to be sensitized in a
significant proportion of patients, and has become an
issue as the number of pet owners is steadily increasing.7
Also, studies have found that AD patients sensitized to
animal dander have a greater likelihood to develop other
respiratory allergic diseases.6 AIT using cat and/or dog
dander has been used for the treatment of allergic asthma
or allergic rhinitis,8,9 whereas the use of cat and/or dog
extract for AIT in AD patients has not been reported.10
Among patients diagnosed with AD according to the
diagnostic criteria of Hanifin and Rajka,11 those sensi-
tized to cat and/or dog dander, regardless of sensitization
to HDM, and underwent AIT were enrolled. The patients
underwent AIT using Hollister‐Stier aqueous extracts
(Hollister‐Stier, Spokane, WA) if (a) they asserted that
their symptoms aggravate when in contact with cat and/
or dog, (b) greater than equal to 3.5 kUA/L (class 3) serum
specific IgE levels to cat or dog dander confirmed by CAP
immunoassay, and (c) inadequately controlled symptoms
with topical therapies. This study has been approved by
the Institutional Review Board of Severance Hospital
(IRB no. 4–2018‐0334). Table 1 shows the demographics,
comorbid allergic diseases, treatment modality, duration
of the treatment, and the treatment progresses of each
patient. There were a total of 19 patients, which consisted
of 4 males and 15 females with an average age of
31.74 ± 9.71 and an age range between 17 and 55.
Seventeen patients had one or more concomitant allergic
diseases, such as allergic rhinitis, allergic asthma, or al-
lergic conjunctivitis, and the remaining two patients had
only AD. Patients were initially assessed for the allergens
sensitized by CAP immunoassay, and their serum specific
IgE levels and IgG4 levels were assessed. Seven patients
were not sensitized to either Dermatophagoides farinae or
Dermatophagoides pteronyssinus and only sensitized to
cat and/or dog dander and the rest of the patients were
sensitized to both HDM and cat/dog dander. The dura-
tion of AIT that the patients underwent ranged from 2 to
58 months. Of the 19 patients, one patient discontinued
AIT due to exacerbation of AD. For the remaining sub-
jects, the symptoms of 17 patients were well‐controlled,
requiring only topical treatment and/or oral anti-
histamines (Figure 1). One patient required systemic
cyclosporine, but only of minimal dosage (25mg/day).
Clinical severity of AD was assessed by Investigator
Global Assessment (IGA) and Eczema Area and Severity
Index (EASI) and a significant reduction of IGA scores
and EASI scores were observed after AIT by the Wilcoxon
signed‐rank test (IGA: n = 19; P= .0009; EASI: n = 19;
P= .0017), (Figures 2).
Specific IgE levels and IgG4 levels were obtained after
1 year in each patient who received AIT for more than
6 months. Specific IgE levels to cat dander and dog
dander were decreased after the AIT when compared
with the initial levels (Figure 3A), and the difference was
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statistically significant by the Wilcoxon signed‐rank test
(P= .005). Specific IgG4 levels to cat and dog dander
were found to be increased after the AIT (Figure 3B), but
the difference was not significant. No adverse events
were observed in the patients, except for the patient
whose symptoms had exacerbated during the treatment,
requiring the cessation of AIT.
Despite the emergence of various novel treatment
modalities in AD including dupilumab, there are still some
patients who remain irresponsive to these treatments. As
the number of pet owners steadily increases7 and the
complete avoidance of animal dander may not be always
feasible, desensitization of the allergens may be the alter-
native treatment option for some patients. Through this
study, we found that patients with AD also could be
benefited from AIT with the cat and/or dog dander, as
verified in allergic asthma and allergic rhinitis.8–10 The
majority of the patients had shown marked improvement
of symptoms, in addition to the decrease in specific IgE
levels and increase in specific IgG4 levels. To our knowl-
edge, this is the first study on the result of AIT in patients
with AD sensitized to cat and/or dog dander. This study
may be limited to the fact that it is an observational study
that the sample size may not be so large and included AD
patients sensitized to other allergens as well. However,
these results may provide insights for new therapeutic
options for AD patients sensitized to animal dander,
especially for severe AD patients with other respiratory
allergic comorbidities who cannot completely avoid
exposure to animal dander.
FIGURE 1 The treatment progress of the patients after AIT.
AIT, allergen‐specific immunotherapy
FIGURE 2 A, The change of the eczema area and severity index (EASI) scores before (pre‐AIT) and after (post‐AIT) allergen‐specific
immunotherapy with animal dander. B, EASI scores from 19 patients were significantly reduced. C, The investigator global assessment
(IGA) score was significantly reduced post‐AIT and D, The patients had higher IGA scores pre‐AIT, whereas the scores post‐AIT were
distributed in lower numbers (n = 19). IGA scores were categorized as follows; 0: clear, 1: almost clear, 2: mild, 3: moderate, 4: severe.
*p< 0.05. AIT, allergen‐specific immunotherapy
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FIGURE 3 A, Specific immunoglobulin E (IgE) levels, and B, Specific IgG4 levels to animal dander before (pre‐AIT) and after
(post‐AIT) allergen‐specific immunotherapy (n = 14). *p< 0.05. AIT, allergen‐specific immunotherapy
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